The United Kingdom and the United States have hammered out a landmark trade agreement that will maintain no duties on UK pharmaceutical products going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these key exports will be held at nothing for a timeframe of the next three years.
This agreement follows earlier warnings to hike tariffs on branded drug imports, with increases floated as high as one hundred percent.
"This deal with the United Kingdom strengthens the worldwide climate for innovative medicines and establishes much-needed balance to American-British medicine commerce," a statement said.
Trade Importance
Pharmaceuticals are one of the UK's largest goods shipped to the America, which is clearly the primary destination for major British pharmaceutical firms.
Export figures indicate that in the one-year period prior to last September, the UK exported medicines worth billions to the US. This value accounted for 17.4% of all goods exports in that span.
"This guarantee protects jobs, boosts investment and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to raise overall public funding on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments exceeded 20%.
Broader Context
This agreement comes amid a long-running tension between the drug companies and the UK government over medicine costs and regulatory access.
These tensions were exacerbated by assertions that American customers were charged several times more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
